Active substances
Insulin aspart + Insulin aspart protamine
- SFDA 6
- Health Canada 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| NOVOMIX 30 FLEXPEN 100U\ML | 30,70 IU/ml,IU/ml | Solution for injection · Subcutaneous use | 5 Pre-filled pen | SAR 189.00 | Biological · Prescription | NOVO NORDISK | Valid |
| NOVOMIX 50 FLEXPEN | 50,50 IU/ml,IU/ml | Suspension for injection · Subcutaneous use | 5 Cartridge | SAR 156.90 | Biological · Prescription | NOVO NORDISK | Valid |
| NOVOMIX 30 PEN FILL | 70,30 IU/ml,IU/ml | Suspension for injection · Subcutaneous use | 5 Cartridge | SAR 162.50 | Biological · Prescription | NOVO NORDISK | Withdrawn by MAH · Not Marketed |
| NOVOMIX 50 PEN FILL | 50,50 IU/ml,IU/ml | Suspension for injection · Subcutaneous use | 5 Cartridge | SAR 133.15 | Biological · Prescription | NOVO NORDISK | Withdrawn by MAH · Not Marketed |
| NOVOMIX 70 FLEXPEN | 70, 30 IU/ml | Suspension for injection · Subcutaneous use | 5 Cartridge | SAR 189.00 | Biological · Prescription | NOVO NORDISK | Withdrawn by MAH · Not Marketed |
| NOVOMIX 70 PEN FILL | 70, 30 IU/ml | Suspension for injection · Subcutaneous use | 5 Cartridge | SAR 168.60 | Biological · Prescription | NOVO NORDISK | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
DIABETES MELLITUS TYPE 1; DIABETES MELLITUS TYPE 2
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| NOVOMIX 30 | 02265435 | 30 UNIT / ML; 70 UNIT / ML | SUSPENSION · SUBCUTANEOUS | NOVO NORDISK CANADA INC |
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.